Merck stock fell in premarket trading Tuesday after the company said sales of its blockbuster HPV vaccine, Gardasil, declined 17% in the fourth quarter of 2024. Shares of the pharmaceutical company slipped 7.

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange,

Key Takeaways Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of estimates.Revenue and adjusted earnings, however, managed to top expectations.Sales of a few Merck drugs were hit by lower international demand and lower pricing in the U.

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 8% in pre-market trading, largely because of weaker than expected 2025 guidance.

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations with Keytruda sales.

Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results , with sales up 6.8% year on year to $15.62 billion. On the other hand, the company’s full-year revenue guidance of $64.85 billion at the midpoint came in 3.